C4 Therapeutics
CCCC
Market cap $119M

1.68 USD

+0.06

3.70%

At close Jun 13, 4:00 PM EDT

After hours

1.66

-0.02

1.19%

1 day

3.70%

5 days

-5.62%

1 month

12.00%

3 months

-16.83%

6 months

-61.64%

Year to date

-54.10%

1 year

-65.07%

5 years

-93.41%

10 years

-93.41%

About: C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Employees: 110

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

3,075% more call options, than puts

Call options by funds: $127K | Put options by funds: $4K

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

17% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 23

1% more funds holding

Funds holding: 113 [Q4 2024] → 114 (+1) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

0.94% less ownership

Funds ownership: 91.23% [Q4 2024] → 90.3% (-0.94%) [Q1 2025]

56% less capital invested

Capital invested by funds: $232M [Q4 2024] → $103M (-$129M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CCCC.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Zacks Investment Research

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago.

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Zacks Investment Research

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Zacks Investment Research

Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now

C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

See News Rankings

Charts implemented using Lightweight Charts™